Invite to take part in a survey as part of the SWITCH study

We are inviting healthcare professionals to take part in a short survey as part of the SWITCH study, a research project funded by the National Institute for Health and Care Research (NIHR). As part of this project, we are looking to explore healthcare professionals’ experiences and opinions on oral SACT medication brand changes.

We are very keen to gather more insights from pharmacists and pharmacy technicians involved in cancer care to better understand how these brand changes impact clinical practice and patient care.

The survey takes around 10 minutes to complete and can be accessed via the link below:

SWITCH study – HCP survey and focus groups

Further information about the study is available at the survey link, including the option for participants to express interest in an additional focus group. Focus group participants will receive a £25 voucher as a thank you for their time.

Your contribution is greatly valued and will help inform future strategies to improve the delivery of cancer services.

If you have any queries about the study or would like more information, then please email us at [email protected].

BOPA Research Subcommittee

Send on behalf of Rebecca Todd

PhD Student

UCL School of Pharmacy

Latest News

By ISOPP Research Committee Chair on 19th September 2025

ISOPP International Symposium 2026 is now open for abstract submissions

I’m excited to share that the ISOPP International Symposium 2026 is now open for abstract submissions! This 24-hour virtual event takes place on March 20, 2026, and will bring together…

Read article
By UK SACT Board Representatives - Joseph Williams and Netty Cracknell on 16th September 2025

Proposals for the reshaping of cancer services in England: funding for innovative cancer treatments

The Royal College of Radiologists (RCR) and the Society of Radiographers (SoR) have published a short document that expands on previous proposals for improving funding arrangements to enable equitable access…

Read article
By BOPA Exec Committee on 15th September 2025

Invitation to visit the BOPA stand at the BOPA Conference in Belfast

Hello All As an Executive Committee we are looking forward to meeting those of you who are signed up to come to the conference in Belfast next month. The BOPA…

Read article
By BOPA Research subcommittee on 14th September 2025

Survey: Fertility and the use of Immune Checkpoint Inhibitor Therapy (Survey from Royal Marsden Hospital)

Immune checkpoint inhibitors, such as atezolizumab, nivolumab and pembrolizumab have transformed the treatment landscape for many cancers. Cancers such as melanoma and Lynch-syndrome related tumours necessitating immune checkpoint inhibitors are…

Read article